Healthcare Sales & Marketing Network News: PCSK9

Searching News Database: PCSK9

HSMN NewsFeed - 19 Jul 2024
Rona Therapeutics Raises $35 Million Series A+ Financing to Advance Innovative Metabolic siRNA Pipeline in Clinic and Next Generation RNA Platforms
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 12 Aug 2020
FDA Accepts Evinacumab Biologics License Application for Priority Review as a Treatment for Patients with HoFH, an Ultra-rare Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Oct 2019
Amgen To Make Repatha(R) (evolocumab) Available Exclusively At Its Lower List Price Option In 2020
Biopharmaceuticals Cardiology Reimbursement

HSMN NewsFeed - 14 Aug 2019
Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol
Biopharmaceuticals Cardiology

HSMN NewsFeed - 4 Feb 2019
CHMP Recommends Approval of Praluent(R) (alirocumab) Injection to Reduce Cardiovascular Risk in People with Established Atherosclerotic Cardiovascular Disease
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 12 Sep 2018
FDA to Review Supplemental Biologics License Application for Praluent(R) (alirocumab)Injection as Potential Treatment to Reduce Major Adverse Cardiovascular Events
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 1 May 2018
Regeneron and Sanofi to Lower Net Price of Praluent(R) (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients
Biopharmaceuticals Reimbursement

HSMN NewsFeed - 23 Mar 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha(R) (evolocumab) Prevents Heart Attacks And Strokes
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 25 Aug 2017
Regeneron and Sanofi to Present New Analyses from Praluent(R) (alirocumab) Injection Trials at the ESC Congress 2017
Biopharmaceuticals Cardiology

HSMN NewsFeed - 28 Jul 2017
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha(R) (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 25 Apr 2017
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 20 Mar 2017
Landmark Outcomes Study Shows that Repatha(R) (evolocumab) Decreases LDL-C to Unprecedented Low Levels and Reduces Risk of Cardiovascular Events with No New Safety Issues
Biopharmaceuticals Cardiology

HSMN NewsFeed - 22 Feb 2017
Repatha(R) (Evolocumab) Receives European Commission Approval For New 420 mg Single-Dose Delivery Option
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 9 Feb 2017
Appeals Court Grants Stay of Permanent Injunction for Praluent(R) (alirocumab) During Appeals Process
Biopharmaceuticals Cardiology Litigation

HSMN NewsFeed - 3 Feb 2017
Amgen Announces Repatha(R) (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study
Biopharmaceuticals Cardiology

HSMN NewsFeed - 9 Jan 2017
The Medicines Company Announces Positive Top-Line Results from Day 180 Interim Analysis in Ongoing ORION-1 Phase 2 Study of Inclisiran (formerly, PCSK9si)
Biopharmaceuticals Cardiology

HSMN NewsFeed - 6 Jan 2017
Regeneron and Sanofi to Appeal U.S. District Court Rulings in Ongoing Patent Litigation Regarding Praluent(R) (alirocumab) Injection
Biopharmaceuticals Cardiology Litigation

HSMN NewsFeed - 5 Dec 2016
Novelion Therapeutics Subsidiary, Aegerion Pharmaceuticals, Enters Into Licensing Agreement With Amryt Pharma for LOJUXTA(R) (lomitapide)
Biopharmaceuticals Cardiology Licensing

HSMN NewsFeed - 17 Nov 2016
Regeneron and Sanofi Announce Praluent(R) (alirocumab) Cardiovascular Outcomes Trial Will Continue as Planned Following Interim Analysis
Biopharmaceuticals

HSMN NewsFeed - 8 Nov 2016
The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
Biopharmaceuticals Cardiology

HSMN NewsFeed - 1 Nov 2016
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
Biopharmaceuticals Cardiology

HSMN NewsFeed - 29 Aug 2016
Regeneron and Sanofi Present Positive Phase 3 Investigational Data for Praluent(R) (alirocumab) Injection in Patients Undergoing LDL Apheresis Therapy at ESC Congress 2016
Biopharmaceuticals Cardiology

HSMN NewsFeed - 29 Aug 2016
New Repatha(R) (evolocumab) Analyses Show Efficacy and Safety Across Risk Groups in Results Presented at ESC Congress 2016
Biopharmaceuticals Cardiology

HSMN NewsFeed - 5 Jul 2016
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in Japan
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 4 Feb 2016
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha(R) (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Biopharmaceuticals

HSMN NewsFeed - 22 Jan 2016
Amgen's Repatha(R) (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
Biopharmaceuticals Regulatory

HSMN NewsFeed - 28 Sep 2015
Regeneron and Sanofi Announce Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia in the European Union
Biopharmaceuticals Cardiology Regulatory

HSMN NewsFeed - 16 Sep 2015
Amgen To Acquire Privately-Held Dezima Pharma
Biopharmaceuticals Cardiology Mergers & Acquisitions

HSMN NewsFeed - 11 Sep 2015
Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha(TM) (Evolocumab)
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 1 Sep 2015
Matinas BioPharma Appoints Cochleate Technology Pioneer Raphael J. Mannino, Ph.D., as Senior Vice President and Chief Technology Officer
Biopharmaceuticals Drug Delivery Personnel

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce FDA Approval of Praluent(R) (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 24 Jul 2015
Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent(R) (alirocumab) for the Treatment of Hypercholesterolemia
Biopharmaceuticals Regulatory

HSMN NewsFeed - 26 Jan 2015
Regeneron and Sanofi Announce Praluent(TM) (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA
Biopharmaceuticals FDA

HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 28 Apr 2014
Pfizer Confirms Prior Discussions with AstraZeneca Regarding a Possible Combination and Its Continuing Interest in a Possible Merger Transaction
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing

HSMN NewsFeed - 18 Dec 2012
AtheroNova Names New Chief Medical Officer
Biopharmaceuticals Cardiology Personnel

HSMN NewsFeed - 11 Jan 2010
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
Biopharmaceuticals

HSMN NewsFeed - 9 May 2007
Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
Biopharmaceuticals Licensing

HSMN NewsFeed - 5 Dec 2006
Alnylam Advances a Systemically Delivered RNAi Therapeutic Targeting PCSK9 for the Treatment of Hypercholesterolemia as New Development Program
Biopharmaceuticals

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.